Cellular histoneModifyingEnzymes · target hub

EZH2

EZH2 (EZH2)

EZH2 is a Histone-modifying enzyme / reader on the Histone-modifying enzymes axis. Validate with UniProt and literature. Indexed under "Histone methyltransferases (HMT/PRMT)" for antibodies and assay guidance.

Back to pathway overviewSearch: EZH2UniProt (Q9Y243)

Research notes

  • Combine with module neighbors to test non-redundant roles of EZH2.
  • Pair phospho/phenotypic readouts with stimulation and inhibitor controls.
  • Validate antibody clone and compartment; include KD/KO controls.

On the pathway hub (sections)

Genetic lesions & expression context (quick reference)

Type / exampleDomain / context (brief)
Expression contextTissue/cell-type–dependent expression
Rare variantsSporadic variants—require validation
Pathway couplingCo-occurs with neighboring nodes

Naming and prevalence vary—annotate clinically with authoritative databases.

Assay readouts for EZH2

  • Histone marks (H3K27me3, H3K4me3—ChIP/WB).
  • Enzyme activity or complex IP.
  • Inhibitor/degrader controls (EZH2, HDAC, BRD).
  • RNA-seq or CUT&Tag downstream.

EZH2 experimental notes

Examples below reflect common literature and public resources (e.g., CCLE, DepMap)—validate genotypes, expression, and passage in your own stocks before committing assays.

[1] Cell lines commonly used for EZH2 studies (examples)

  • Tool lines: HeLa, MCF-7, Jurkat, HEK293T—screen by EZH2 expression (CCLE/DepMap).
  • Combine with neighbors (EZH1, SUZ12, EED, DOT1L) via KD/pharmacology.
  • Overexpression/rescue in HEK293T supports mechanism and IP.
  • Isogenic/CRISPR models separate dependency from bypass.

[2] Cell samples for EZH2 Western blot

  • Whole-cell lysates; phosphatase inhibitors for phospho blots.
  • Optimize stimulation time courses per ligand/stress.
  • Controls: KD/KO or inhibitors.
  • BCA normalization; subcellular fractionation when needed.

[3] Tissue samples for EZH2 Western blot

  • Matched tumor/adjacent frozen tissues.
  • Mouse models—mind species cross-reactivity.
  • Primary cells/PDCs when approved.
  • FFPE needs specialized extraction; frozen preferred for phospho.

[4] Cell samples for EZH2 immunoprecipitation

  • Tagged overexpression: HEK293T FLAG/HA-EZH2.
  • Endogenous IP: high-expression lines.
  • Stimulation enriches interactions.
  • Controls: isotype IgG, empty vector, KO.

Human tissues and primary cells require ethics/IRB approval; tumors are heterogeneous—record histotype, site, and preservation conditions.

Bypass & related pathways

Models & genetics note

Overexpression vs endogenous EZH2 can differ in dosage, splicing, and compartmentation.

Quick search presets

EZH2EZH2 antibodyhistone modification antibody

EZH2-related antibodies (keyword-biased)

Adds EZH2 keyword bias atop the 组蛋白修饰酶 antibody pool—if sparse, use presets above or global search.

Neighboring targets (same hub)

EZH1SUZ12EEDDOT1LPRMT1PRMT5PRMT6KMT2A

External databases & resources

FAQ

This content supports research reagents and pathway education—not medical advice. Annotate mutations, drug indications, and protocols with authoritative databases, datasheets, and institutional oversight.

Last reviewed: 2026-05-18

Related on this site

See the cellular histoneModifyingEnzymes hub for neighboring targets—cross-check PI3K, MAPK, and transmembrane transport pages as needed.

Cellular histoneModifyingEnzymes·PI3K/Akt/mTOR·MAPK/ERK·Receptor tyrosine kinase·Transmembrane transport